Journal ArticleDOI
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Michael Fuchs,Helen Goergen,Carsten Kobe,Georg Kuhnert,Andreas Lohri,Richard Greil,Stephanie Sasse,Max S. Topp,Erhardt Schäfer,Bernd Hertenstein,Martin Soekler,Martin Vogelhuber,Josee M. Zijlstra,Ulrich Keller,Stefan W. Krause,Martin Wilhelm,Georg Maschmeyer,Julia Thiemer,Ulrich Dührsen,Julia Meissner,Andreas Viardot,Hans Theodor Eich,Christian Baues,Volker Diehl,Andreas Rosenwald,Bastian von Tresckow,Markus Dietlein,Peter Borchmann,Andreas Engert +28 more
Reads0
Chats0
TLDR
In early-stage favorable HL, a positive PET after two cycles ABVD indicates a high risk for treatment failure, particularly when a Deauville score of 4 is used as a cutoff for positivity in PET-2-positive patients.Abstract:
PURPOSECombined-modality treatment (CMT) with 2× ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiotherapy is standard of care for patients with early-stage favorable...read more
Citations
More filters
Journal ArticleDOI
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Alexander R. Lyon,Teresa López-Fernández,Liam Couch,Riccardo Asteggiano,Marianne C Aznar,Jutta Bergler-Klein,Giuseppe Boriani,Daniela Cardinale,Raul Cordoba,Bernard Cosyns,D Cutter,Evandro de Azambuja,W. De Boer,Susan Dent,Dimitrios Farmakis,Sofie Gevaert,D. Gorog,A. Herrmann,Daniel J. Lenihan,Javid Moslehi,Brenda Moura,Sonja S Salinger,R. Stephens,Thomas M. Suter,Sebastian Szmit,Juan Tamargo,Paaladinesh Thavendiranathan,Carlo G. Tocchetti,P. Van Der Meer,Helena J H van der Pal +29 more
Journal ArticleDOI
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Alexander R. Lyon,Teresa López-Fernández,Liam Couch,Riccardo Asteggiano,Marianne C. Aznar,Jutta Bergler-Klein,Giuseppe Boriani,Daniela Cardinale,Raul Cordoba,Bernard Cosyns,D Cutter,Evandro de Azambuja,W. De Boer,Susan Dent,Dimitrios Farmakis,Sofie Gevaert,Diana A. Gorog,A. Herrmann,Daniel J. Lenihan,Javid Moslehi,Brenda Moura,Sonja S Salinger,R. Stephens,Thomas M. Suter,Sebastian Szmit,Juan Tamargo,Paaladinesh Thavendiranathan,Carlo G. Tocchetti,P. Van Der Meer,Helena J H van der Pal +29 more
Journal ArticleDOI
Hodgkin lymphoma, version 2.2020
Richard T. Hoppe,Ranjana H. Advani,Weiyun Z. Ai,Richard F. Ambinder,Philippe Armand,Celeste M. Bello,Cecil M. Benitez,Philip J. Bierman,Kirsten M Boughan,Bouthaina S. Dabaja,Leo I. Gordon,Francisco J. Hernandez-Ilizaliturri,Alex F. Herrera,Ephraim P. Hochberg,Jiayi Huang,Patrick B. Johnston,Mark S. Kaminski,Vaishalee P. Kenkre,Nadia Khan,Ryan C. Lynch,Kami J. Maddocks,Jonathan McConathy,Matthew McKinney,Monika L. Metzger,David S. Morgan,Carolyn Mulroney,Rachel Rabinovitch,Karen C. Rosenspire,Stuart Seropian,Randa Tao,Jane N. Winter,Joachim Yahalom,Jennifer L. Burns,Ndiya Ogba +33 more
TL;DR: The introduction of less toxic and more effective regimens has significantly advanced HL cure rates and this portion of the NCCN Guidelines focuses on the management of classic HL.
Journal ArticleDOI
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Peter Borchmann,Annette Plütschow,Carsten Kobe,Richard Greil,Julia Meissner,Max S. Topp,Helmut Ostermann,Judith Dierlamm,Johannes Mohm,Julia Thiemer,Martin Sökler,Andrea Kerkhoff,Miriam Ahlborn,Teresa V Halbsguth,Sonja Martin,Ulrich Keller,Stefan Balabanov,Thomas Pabst,Martin Vogelhuber,Andreas Hüttmann,Martin Wilhelm,Josée M. Zijlstra,Alden A. Moccia,Georg Kuhnert,Paul J Bröckelmann,Bastian von Tresckow,Bastian von Tresckow,Michael Fuchs,Beate Klimm,Andreas Rosenwald,Hans Theodor Eich,Christian Baues,Simone Marnitz,Michael Hallek,Volker Diehl,Markus Dietlein,Andreas Engert +36 more
TL;DR: The German Hodgkin Study Group HD17 trial as discussed by the authors investigated whether radiotherapy can be omitted without loss of efficacy in patients who have a complete metabolic response after receiving two cycles of escalated doses of etoposide, cyclophosphamide, and doxorubicin.
Journal ArticleDOI
FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma-An Updated Overview.
Conrad-Amadeus Voltin,Jasmin Mettler,Jirka Grosse,Markus Dietlein,Christian Baues,Christine Schmitz,Peter Borchmann,Carsten Kobe,Dirk Hellwig +8 more
TL;DR: Novel measures such as metabolic tumor volume or total lesion glycolysis have recently been recognized by several working groups and may further increase the diagnostic and prognostic value of FDG-PET in the future.
References
More filters
Journal ArticleDOI
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Andreas Engert,Annette Plütschow,Hans Theodor Eich,Andreas Lohri,Bernd Dörken,Peter Borchmann,Bernhard Berger,Richard Greil,Kay C. Willborn,Martin Wilhelm,Jürgen Debus,Michael J. Eble,Martin Sökler,A. D. Ho,Andreas Rank,Arnold Ganser,Lorenz Trümper,Carsten Bokemeyer,Hartmut Kirchner,Jörg Schubert,Zdenek Kral,Michael Fuchs,Hans Konrad Müller-Hermelink,Rolf-Peter Müller,Volker Diehl +24 more
TL;DR: In patients with early-stage Hodgkin's lymphoma and a favorable prognosis, treatment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy is as effective as, and less toxic than, four cycles ofABVD following by 30 Gy ofinvolved- field radiation therapy.
Journal ArticleDOI
Report on the First International Workshop on interim-PET scan in lymphoma
TL;DR: The aim of the workshop was to reach a consensus on simple, reproducible criteria for interim-PET interpretation in Hodgkin lymphoma and diffuse large B-cell lymphoma, and to launch two or more international validation studies, in an attempt to validate these rules.
Journal ArticleDOI
Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study
Anthony J. Swerdlow,Craig D. Higgins,Paul Smith,David Cunningham,Barry W. Hancock,Alan Horwich,Peter Hoskin,Andrew Lister,John Radford,Ama Z. S. Rohatiner,David C. Linch +10 more
TL;DR: The risk of death from myocardial infarction after treatment for Hodgkin disease remains high for at least 25 years, and is related to supradiaphragmatic radiotherapy but may also be related to anthracycline and vincristine treatment.
Journal ArticleDOI
Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines
Theodore Girinsky,Richard W.M. van der Maazen,Lena Specht,Berthe M.P. Aleman,Philip Poortmans,Yolande Lievens,Paul Meijnders,Mithra Ghalibafian,J.H. Meerwaldt,Evert M. Noordijk +9 more
TL;DR: The concept of involved-node radiotherapy (INRT) described here is the first attempt to reduce the size of radiation fields compared to the classic involved fields used in adult patients.
Journal ArticleDOI
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease
Andrea Gallamini,Luigi Rigacci,Francesco Merli,Luca Nassi,Alberto Bosi,Isabella Capodanno,Stefano Luminari,Umberto Vitolo,Rosaria Sancetta,Emilio Iannitto,Livio Trentin,Caterina Stelitano,Silvia Tavera,Alberto Biggi,Antonio Castagnoli,Annibale Versari,Michele Gregianin,Ettore Pelosi,Pierfederico Torchio,Alessandro Levis +19 more
TL;DR: 18F-FDG-PET scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease was able to predict treatment outcome in 103/108 (95%) of the patients, and the positive predictive value of a PET-2 was 90% and the negative predictive value was 97%.
Related Papers (5)
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Andreas Engert,Annette Plütschow,Hans Theodor Eich,Andreas Lohri,Bernd Dörken,Peter Borchmann,Bernhard Berger,Richard Greil,Kay C. Willborn,Martin Wilhelm,Jürgen Debus,Michael J. Eble,Martin Sökler,A. D. Ho,Andreas Rank,Arnold Ganser,Lorenz Trümper,Carsten Bokemeyer,Hartmut Kirchner,Jörg Schubert,Zdenek Kral,Michael Fuchs,Hans Konrad Müller-Hermelink,Rolf-Peter Müller,Volker Diehl +24 more
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Peter Johnson,Massimo Federico,Amy A Kirkwood,Alexander Fosså,Leanne Berkahn,Angelo Michele Carella,Francesco d'Amore,Gunilla Enblad,Antonella Franceschetto,Michael J. Fulham,Stefano Luminari,Michael O'Doherty,Pip Patrick,Thomas Roberts,Gamal Sidra,L. Stevens,Paul Smith,Judith Trotman,Z. Viney,John Radford,Sally F. Barrington +20 more
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Andreas Engert,Heinz Haverkamp,Carsten Kobe,Jana Markova,Christoph Renner,A. D. Ho,Josée M. Zijlstra,Zdenek Kral,Michael Fuchs,Michael Hallek,Lothar Kanz,Hartmut Döhner,Bernd Dörken,Nicole Engel,Max S. Topp,Susanne Klutmann,Holger Amthauer,Andreas Bockisch,Regine Kluge,Clemens Kratochwil,Otmar Schober,Richard Greil,Reinhard Andreesen,Michael Kneba,Michael Pfreundschuh,Harald Stein,Hans Theodor Eich,Rolf-Peter Müller,Markus Dietlein,Peter Borchmann,Volker Diehl +30 more